MedPath

Bed Rest, Alternate Daily Fasting and Incretin Effect

Not Applicable
Completed
Conditions
Metabolic Syndrome
Type 2 Diabetes
Critical Illness
Interventions
Other: Bed rest
Other: OGTT
Other: IVGTT
Other: Cognitive testing
Other: Muscle and fat biopsies
Other: Dual-energy X-ray Absorptiometry (DXA) scan
Other: MRI
Registration Number
NCT02134860
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

Bed rest produces insulin resistance in healthy volunteers. In this study the investigators aim to investigate the effect of 8 days bed rest on the incretin effect and how alternate daily fasting affects cognitive function and the insulin resistance produced by bed rest.

The subjects will be randomized to either 3 meals a day (isocaloric diet), alternate daily fasting or one meal/day every second day (25% of daily calorie need) and four meals/day every second (175% of daily calorie need).

The investigators hypothesize:

1. Bed rest reduces the incretin effect

2. Alternate daily fasting improves the cognitive function (memory and concentration) compared to isocaloric diet

3. Alternate daily fasting reduces insulin resistance produced by bed rest compared to isocaloric diet

Detailed Description

All subjects will undergo 8 days of bedrest. Outcome measures will be performed before, under and immediately after the bed rest period.

The individual study period will be 10 days in total.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
20
Inclusion Criteria
  • BMI<25kg/m2
  • VO2 max normal for age
Exclusion Criteria
  • Tobacco smoking
  • Alcohol ingestion > 14 units per week
  • Diabetes in nearby relatives
  • Resection of the small intestine
  • History of gastric bypass surgery
  • Risk of deep venous thrombosis
  • Female

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Isocaloric dietOGTT3 daily meals
Alternate daily fastingMRIOne meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
Isocaloric dietDual-energy X-ray Absorptiometry (DXA) scan3 daily meals
Alternate daily fastingIVGTTOne meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
Alternate daily fastingMuscle and fat biopsiesOne meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
Isocaloric dietBed rest3 daily meals
Isocaloric dietIVGTT3 daily meals
Isocaloric dietCognitive testing3 daily meals
Isocaloric dietMuscle and fat biopsies3 daily meals
Isocaloric dietMRI3 daily meals
Alternate daily fastingBed restOne meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
Alternate daily fastingCognitive testingOne meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
Alternate daily fastingOGTTOne meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
Alternate daily fastingDual-energy X-ray Absorptiometry (DXA) scanOne meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
Primary Outcome Measures
NameTimeMethod
Cognitive function18 months

Evaluated by cognitive testing and functional Magnetic Resonance imaging (MRI)

Incretin effect24 weeks

Measured by Insulin levels during Oral glucose tolerance test (OGTT) and Intravenous glucose tolerance test (IVGTT)

Insulin resistance12 weeks

Evaluated by insulin resistance indexes, HOMA-IR and Matsuda index

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rigshospitalet

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath